Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

Leukemia

Volumn 29, Issue 3, 2015, Pages 741-744

  Pardanani, A ^a   Abdelrahman, R A ^a   Finke, C ^a   Lasho, T T ^a   Begna, K H ^a   Al Kali, A ^a   Hogan, W J ^a   Litzow, M R ^a   Hanson, C A ^a   Ketterling, R P ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMELOTINIB; ASXL1 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; CALRETICULIN; CALRETICULIN, HUMAN; GENETIC MARKER; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; MPL PROTEIN, HUMAN; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; REPRESSOR PROTEIN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ANEMIA; BLOOD SAMPLING; CLINICAL PROTOCOL; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENETIC MARKER; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; LETTER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MICROCAPSULE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SPLEEN SIZE; SURVIVAL; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; DRUG ADMINISTRATION; GENE EXPRESSION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; CALRETICULIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; SURVIVAL ANALYSIS;

EID: 84924585836     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.306     Document Type: Letter

References (9)

1. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood 2014; 124: 2507-2513.
2. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofi brosis. Leukemia 2013; 27: 1861-1869.
3. Pardanani A, Gotlib J, Gupta V, Roberts A, Wadleigh M, Sirhan S et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013; 122.
4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
5. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322-1327.
6. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108 : 1497-1503.
7. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494-1500.
8. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810.
9. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014; 123: 2157-2160.